Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 13-20

  Kartal Yandım, Melis ^a   Apohan, Elif ^a,b   Baran, Yusuf ^a  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

Cancer therapy; Ceramide; Drug resistance; Glucosylceramide; Glucosylceramide synthase; Sphingolipid

Indexed keywords

CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; DOXORUBICIN; GLUCOSYLCERAMIDE; LACTOFERRICIN; PACLITAXEL; RESVERATROL; TAMOXIFEN; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COMPLEX FORMATION; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; HUMAN; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 84872356927     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1984-x     Document Type: Review

References (91)

1. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604-616
2. Saddoughi SA, Song P, Ogretmen B (2008) Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 49:413-440
3. Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G (2006) Inhibitors of sphingolipid metabolism enzymes. Bba-Biomembranes 1758:1957-1977
4. Tettamanti G, Bassi R, Viani P, Riboni L (2003) Salvage pathways in glycosphingolipid metabolism. Biochimie 85(3-4):423-437
5. Ozbayraktar FBK, Ulgen KO (2010) Drug target identification in sphingolipid metabolism by computational systems biology tools: metabolic control analysis and metabolic pathway analysis. J Biomed Inform 43:537-549
6. Ekiz HA, Baran Y (2010) Therapeutic applications of bioactive sphingolipids in hematological malignancies. Int J Cancer 127:1497-1506
7. Ozbayraktar FB, Ulgen KO (2009) Molecular facets of sphingolipids: mediators of diseases. Biotechnol J 4:1028-1041
8. Tyteca D, D'Auria L, Der Smissen PV, Medts T, Carpentier S, Monbaliu JC, de Diesbach P, Courtoy PJ (2010) Three unrelated sphingomyelin analogs spontaneously cluster into plasma membrane micrometric domains. Bba-Biomembranes 1798:909-927
9. Patwardhan GA, Liu YY (2011) Sphingolipids and expression regulation of genes in cancer. Prog Lipid Res 50:104-114
10. Snook CF, Jones JA, Hannun YA (2006) Sphingolipid-binding proteins. Biochim Biophys Acta 1761:927-946
11. Reynolds CP, Maurer BJ, Kolesnick RN (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206:169-180
12. Sabourdy F, Kedjouar B, Sorli SC, Colie S, Milhas D, Salma Y, Levade T (2008) Functions of sphingolipid metabolism in mammals - lessons from genetic defects. Bba-Mol Cell Biol L 1781:145-183
13. Cuvillier O, Levade T (2003) Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacol Res 47:439-445
14. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, Kelly S, Allegood JC, Liu Y, Peng Q, Ramaraju H, Sullards M, Cabot M, Merrill AH (2006) Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Bba-Biomembranes 1758:1864-1884
15. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Bio 9:139-150
16. Bartke N, Hannun YA (2009) Bioactive sphingolipids: metabolism and function. J Lipid Res 50(Suppl):S91-S96
17. Perry RJ, Ridgway ND (2005) Molecular mechanisms and regulation of ceramide transport. Biochim Biophys Acta 1734:220-234
18. Kitatani K, Idkowiak-Baldys J, Hannun YA (2008) The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 20:1010-1018
19. Dyatlovitskaya EV, Kandyba AG (2006) Role of biologically active sphingolipids in tumor growth. Biochemistry (Moscow) 71:10-17
20. Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G (2006) Inhibitors of sphingolipid metabolism enzymes. Biochim Biophys Acta 1758:1957-1977
21. Senkal CE, Ponnusamy S, Rossi MJ, Bialewski J, Sinha D, Jiang JC, Jazwinski SM, Hannun YA, Ogretmen B (2007) Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 6:712-722
22. Parihar A, Parihar MS, Nazarewicz R, Ghafourifar P (2010) Importance of cytochrome c redox state for ceramide-induced apoptosis of human mammary adenocarcinoma cells. Bba Gen Subjects 1800:646-654
23. Wang J, Lv XW, Du YG (2009) Potential mechanisms involved in ceramide-induced apoptosis in human colon cancer HT29 cells. Biomed Environ Sci 22:76-85
24. Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE, Cabot MC (2004) Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 45:933-940
25. Yoshizaki F, Nakayama H, Wahara C, Takamori K, Ogawa H, Iwabuchi K (2008) Role of glycosphingolipid-enriched microdomains in innate immunity: microdomain-dependent phagocytic cell functions. Bba-Gen Subjects 1780:383-392
26. Hakomori SI (2008) Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Bba-Gen Subjects 1780:325-346
27. Bleicher RJ, Cabot MC (2002) Glucosylceramide synthase and apoptosis. Bba Mol Cell Biol L 1585:172-178
28. Barreto-Bergter E, Pinto MR, Rodrigues ML (2004) Structure and biological functions of fungal cerebrosides. An Acad Bras Cienc 76:67-84
29. Maunula S, Bjorkqvist YJE, Slotte JP, Ramstedt B (2007) Differences in the domain forming properties of N-palmitoylated neutral glycosphingolipids in bilayer. Bba-Biomembranes 1768:336-345
30. Degroote S, Wolthoorn J, van Meer G (2004) The cell biology of glycosphingolipids. Semin Cell Dev Biol 15:375-387
31. Duclos RI (2001) The total syntheses of D-erythro-sphingosine, N-palmitoylsphingosine (ceramide), and glucosylceramide (cerebroside) via an azidosphingosine analog. Chem Phys Lipids 111:111-138
32. van Meer G, Holthuis JC (2000) Sphingolipid transport in eukaryotic cells. Biochim Biophys Acta 1486:145-170
33. Aerts JMFG, Ghisaidoobe A, Bikker P, de Bruijn ACJ, Godschalk FD, Rogaar E, Guijt MC, Hagens P, Halma JM, van't Hart SM, Luitjens SB, van Rixel VHS, Wijzenbroek M, Zweegers T, Donker-Koopman WE, Strijland A, Boot R, van der Marel G, Overkleeft HS, van den Berg RJBHN (2011) Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars. Acs Med Chem Lett 2:119-123
34. Tuuf J, Kjellberg MA, Molotkovsky JG, Hanada K, Mattjus P (2011) The intermembrane ceramide transport catalyzed by CERT is sensitive to the lipid environment. Biochim Biophys Acta 1808:229-235
35. Liu YY, Han TY, Giuliano AE, Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274:1140-1146
36. Leipelt M, Warnecke D, Zahringer U, Ott C, Muller F, Hube B, Heinz E (2001) Glucosylceramide synthases, a gene family responsible for the biosynthesis of glycosphingolipids in animals, plants, and fungi. J Biol Chem 276:33621-33629
37. Hillig I, Leipelt M, Ott C, Zahringer U, Warnecke D, Heinz E (2003) Formation of glucosylceramide and sterol glucoside by a UDP-glucose-dependent glucosylceramide synthase from cotton expressed in Pichia pastoris. FEBS Lett 553:365-369
38. Ito M, Komori H (1996) Homeostasis of cell-surface glycosphingolipid content in B16 melanoma cells. Evidence revealed by an endoglycoceramidase. J Biol Chem 271:12655-12660
39. Inokuchi J, Jimbo M, Momosaki K, Shimeno H, Nagamatsu A, Radin NS (1990) Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res 50:6731-6737
40. Lafont D, Bouchu MN, Girard-Egrot A, Boullanger P (2001) Syntheses and interfacial behaviour of neoglycolipid analogues of glycosyl ceramides. Carbohydr Res 336:181-194
41. Miura T, Kajimoto T, Jimbo M, Yamagishi K, Inokuchi JC, Wong CH (1998) Synthesis and evaluation of morpholino- and pyrrolidinosphingolipids as inhibitors of glucosylceramide synthase. Bioorg Med Chem 6:1481-1489
42. Chujor CS, Feingold KR, Elias PM, Holleran WM (1998) Glucosylceramide synthase activity in murine epidermis: quantitation, localization, regulation, and requirement for barrier homeostasis. J Lipid Res 39:277-285
43. Abe A, Radin NS, Shayman JA, Wotring LL, Zipkin RE, Sivakumar R, Ruggieri JM, Carson KG, Ganem B (1995) Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 36:611-621
44. Hillig I, Warnecke D, Heinz E (2005) An inhibitor of glucosylceramide synthase inhibits the human enzyme, but not enzymes from other organisms. Biosci Biotechnol Biochem 69:1782-1785
45. Di Sano F, Di Bartolomeo S, Fazi B, Fiorentini C, Matarrese P, Spinedi A, Piacentini M (2002) Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis. Cell Death Differ 9:693-695
46. Ichikawa S, Hirabayashi Y (1998) Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 8:198-202
47. Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, Wang J, Mu HJ, Zhang B, Qiao WZ, Xie KM (2008) Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32:475-480
48. Compain P, Martin OR, Boucheron C, Godin G, Yu L, Ikeda K, Asano N (2006) Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease. ChemBioChem 7:1356-1359
49. Basu S, Kaufman B, Roseman S (1968) Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain. J Biol Chem 243:5802-5804
50. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K (2000) Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485:63-99
51. Liu Y, Xie KM, Yang GQ, Bai XM, Shi YP, Mu HJ, Qiao WZ, Zhang B, Xie P (2010) GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line. Cancer Chemother Pharmacol 66:433-439
52. Turzanski J, Grundy M, Shang S, Russell N, Pallis M (2005) P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol 33:62-72
53. Fujikawa K, Nohara T, Imamura A,Ando H, Ishida H, Kiso M (2010) A cyclic glucosyl ceramide acceptor as a versatile building block for complex ganglioside synthesis. Tetrahedron Lett 51:1126-1130
54. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC (2004) Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3:633-639
55. Sietsma H, Veldman RJ, Kok JW (2001) The involvement of sphingolipids in multidrug resistance. J Membr Biol 181:153-162
56. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC (1998) Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18:475-480
57. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y, Iwai K, Tashima M, Uchiyama T, Okazaki T (2003) Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 9:415-423
58. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272:1682-1687
59. Liu YY, Han TY, Giuliano AE, Cabot MC (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15:719-730
60. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC (1996) Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271:19530-19536
61. Chapman JV, Gouaze-Andersson V, Cabot MC (2010) Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity. Int J Oncol 37:1591-1597
62. Gouaze-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC (2007) Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim Biophys Acta 1771:1407-1417
63. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, Gouaze-Andersson V, Consoli DP, Cabot MC (2008) A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 22:2541-2551
64. Albi MVME (2008) Sphingolipid metabolism inhibitors and cell function. Open Enzym Inhib J 1:72-79
65. van Vlerken LE, Duan Z, Seiden MV, Amiji MM (2007) Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 67:4843-4850
66. Siddiqui A, Patwardhan GA, Liu YY, Nazzal S (2010) Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int J Pharm 400:251-259
67. Patwardhan GA, Zhang QJ, Yin D, Gupta V, Bao J, Senkal CE, Ogretmen B, Cabot MC, Shah GV, Sylvester PW, Jazwinski SM, Liu YY (2009) A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. PLoS ONE 4:e6938
68. Sun Y, Zhang T, Gao P, Meng B, Gao Y, Wang X, Zhang J, Wang H, Wu X, Zheng W, Zhou G (2010) Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs. Breast Cancer Res Treat 121:591-599
69. Zhang X, Li J, Qiu Z, Gao P, Wu X, Zhou G (2009) Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi). Cancer Biol Ther 8:1117-1121
70. Baran Y, Bielawski J, Ogretmen B, Gunduz U (2011) Inhibition of glucosylceramide synthase by PDMP resensitizes multidrug-resistant human chronic myeloid leukemia cells to Imatinib. J Can Res Clin Oncol 137(10):1535-1544
71. Kok JW, Sietsma H (2004) Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 5:375-382
72. Radin NS (1994) Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase. Mol Chem Neuropathol 21:111-127
73. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP (1999) Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91:1138-1146
74. Radin NS (1999) Chemotherapy by slowing glycosphingolipid synthesis. Biochem Pharmacol 57:589-595
75. Weiss M, Hettmer S, Smith P, Ladisch S (2003) Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res 63:3654-3658
76. Di Sano F, Fazi B, Citro G, Lovat PE, Cesareni G, Piacentini M (2003) Glucosylceramide synthase and its functional interaction with RTN-1C regulate chemotherapeutic-induced apoptosis in neuroepithelioma cells. Cancer Res 63:3860-3865
77. Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65:3861-3867
78. Dijkhuis AJ, Klappe K, Jacobs S, Kroesen BJ, Kamps W, Sietsma H, Kok JW (2006) PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol Cancer Ther 5:593-601
79. Furlong SJ, Ridgway ND, Hoskin DW (2008) Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. Int J Oncol 32:537-544
80. Kraveka JM, Li L, Szulc ZM, Bielawski J, Ogretmen B, Hannun YA, Obeid LM, Bielawska A (2007) Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 282:16718-16728
81. Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J, Mehendale H, Cabot MC, Li YT, Jazwinski SM (2010) Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 9:145
82. Rath G, Schneider C, Langlois B, Sartelet H, Morjani H, Btaouri HE, Dedieu S, Martiny L (2009) De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. Int J Biochem Cell Biol 41:1165-1172
83. Liu YY, Patwardhan GA, Bhinge K, Gupta V, Gu X, Jazwinski SM (2011) Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res 71:2276-2285
84. Cakir Z, Saydam G, Sahin F, Baran Y (2011) The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60 acute myeloid leukemia cells. J Cancer Res Clin Oncol 137:279-286
85. Kartal M, Saydam G, Sahin F, Baran Y (2011) Resveratrol triggers apoptosis by increasing intracellular concentrations of ceramides in chronic myeloid leukemia cells. Nutrit Cancer An Internat J 63(4):637-644
86. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B (2007) Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 282:10922-10934
87. Camgoz A, Ural AU, Avcu F, Baran Y (2011) Targeting ceramide metabolism to increase intracellular concentrations of apoptotic ceramide increased cytotoxic effects of nilotinib in human chronic myeloid leukemia cells. Leuk and Lymph 52(8):1574-1584
88. Gencer AB, Ural AU, Avcu F, Baran Y (2011) Dasatinib induces apoptosis through increasing de novo generation or accumulation of ceramides in human K562 and Meg-01 chronic myeloid leukemia cells. Annals of Hemat 90(11):1265-1275
89. Bassoy EY, Baran Y (2012) Bioactive sphingolipids in docetaxel-induced apoptosis in human prostate cancer cells. Biomed Pharmacot 66(2):103-110
90. Olshefski RS, Ladisch S (2001) Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 93:131-138
91. Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, Wang J, Mu HJ, Zhang B, Qiao WZ, Xie KM (2008) Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32:475-480